CORTCorcept TherapeuticsSigning up patients
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms · Endometrial Cancer
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.4
3 insiders sold shares within a month
Since Aug 26, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 2
- Patients
- 270 (planned)
- Started
- Apr 11, 2025
- Main results expected
- Aug 2026
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Date of first dose until PD or death, up to 18 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.4, since 2026-08-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06906341 · record last updated 2026-07-16 · checked 2026-11-09 15:36 UTC